<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540747</url>
  </required_header>
  <id_info>
    <org_study_id>Mel_FF</org_study_id>
    <nct_id>NCT01540747</nct_id>
  </id_info>
  <brief_title>Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <brief_summary>
    <textblock>
      To evaluate the effects of melatonin supplementation on the main in vitro fertilization (IVF)&#xD;
      outcomes during ovarian stimulation in patients with Polycystic ovarian syndrome (PCOS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that causes infertility due&#xD;
      to anovulation in women of reproductive age. Anovulation and also decreased oocyte and embryo&#xD;
      quality may be cause of infertility in women with PCOS. Furthermore, the reactive oxygen&#xD;
      species (ROS) induce oxidative stress which may be responsible for poor oocyte quality. The&#xD;
      ROS generation from mononuclear cells is elevated in women with PCOS and a significant&#xD;
      increment of lipid peroxidation products in women with PCOS has been reported.&#xD;
&#xD;
      Melatonin is a documented powerful free radical scavenger and a broad spectrum antioxidant.&#xD;
      It has been observed that a non-PCOS group co-treated with inositol, folic acid, and&#xD;
      melatonin (Inofolic Plus by LO.LI.Pharma) results in a significantly greater mean number of&#xD;
      mature oocytes, and a lower mean number of immature oocytes in patients with low oocyte&#xD;
      quality history when compared to treatment only with inositol and folic acid (Inofolic by&#xD;
      LO.LI.Pharma).&#xD;
&#xD;
      The aim of the study is to evaluate the possible effects of melatonin supplementation on the&#xD;
      main IVF outcomes during ovarian stimulation of patients with PCOS.&#xD;
&#xD;
      From July 2009 to December 2011, 358 patients with PCOS (Rotterdam criteria) were enrolled in&#xD;
      this prospective randomized controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Number of mature oocytes</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>embryo quality</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantation rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of FSH administered</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stimulation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <description>Endometrial thickness on the day of human chorionic gonadotropin (hCG) administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate or severe ovaric hyperstimulation syndrome (OHSS)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Inofolic plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>178 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inofolic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + folic acid + melatonin</intervention_name>
    <description>Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)</description>
    <arm_group_label>Inofolic plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + folic acid</intervention_name>
    <description>Myo-inositol (2000mg) + folic acid (200 mcg)</description>
    <arm_group_label>Inofolic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of PCOS&#xD;
&#xD;
          -  irregular menstrual cycle (&gt; than 28-30 days)&#xD;
&#xD;
          -  normal uterine cavity&#xD;
&#xD;
          -  body mass index of 20 to 26 Kg/m2&#xD;
&#xD;
          -  first IVF treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of tubal, uterine, genetics and male causes of infertility&#xD;
&#xD;
          -  diagnosis of cancer&#xD;
&#xD;
          -  hormonal treatment in the last six months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Praxi Pro Vita Centro di Fertilit√†</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrafollicular melatonin</keyword>
  <keyword>PCOS</keyword>
  <keyword>embryos quality</keyword>
  <keyword>oocytes quality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

